Comparative Pharmacology
Head-to-head clinical analysis: CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER versus FETROJA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER versus FETROJA.
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER vs FETROJA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. It is resistant to many beta-lactamases.
Cefiderocol is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP3, and is stable against a broad range of beta-lactamases, including carbapenemases, due to its ability to penetrate the outer membrane via the bacterial iron transport system.
1-2 g IV every 6-8 hours. Maximum 12 g/day.
1 gram intravenously over 3 hours every 8 hours in patients 18 years and older with creatinine clearance ≥ 60 mL/min.
None Documented
None Documented
Terminal elimination half-life: 0.7-1.1 hours (normal renal function); prolonged to 5-13 hours in severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life: 2.5-3.5 hours; prolonged in renal impairment (e.g., up to 5-6 hours in severe renal impairment), requiring dose adjustment
Renal: 85-90% unchanged via glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Renal: approximately 65-70% of the dose excreted unchanged in urine; biliary/fecal: minimal (<1%)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic